Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead product candidate, CTI-1601, is a recombinant fusion protein that is being developed for the treatment of Friedreich's ataxia, a rare genetic disease that causes progressive damage to the nervous system. Larimar Therapeutics was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.